福泰制药Vertex Pharmaceuticals（VRTX）2025年第二季度财报电话会议纪要「NASDAQ」（英文版）（20页）.pdf

1、2025 Vertex Pharmaceuticals Incorporated 2025 Vertex Pharmaceuticals Incorporated FIRST QUARTER 2025 FINANCIAL RESULTS2025 Vertex Pharmaceuticals IncorporatedSecond Quarter 2025Financial ResultsAugust 4,2025Presentation intended for the investment community2025 Vertex Pharmaceuticals Incorporated 2A

2、gendaIntroduction Susie Lisa,CFA,Senior Vice President,Investor RelationsCEO Perspective and Pipeline Update Reshma Kewalramani,M.D.,Chief Executive Officer and PresidentCommercial Update Duncan McKechnie,Executive Vice President and Chief Commercial Officer Financial Results Charlie Wagner,Executiv

3、e Vice President and Chief Operating&Financial Officer2025 Vertex Pharmaceuticals Incorporated 3Safe harbor statement&non-GAAP financial measuresThis presentation contains forward-looking statements that are subject to risks,uncertainties and other factors.All statements other than statements of his

4、torical fact are statements that could be deemed forward-looking statements,including all statements regarding the intent,belief,or current expectation of Vertex and members of the Vertex senior management team.Forward-looking statements are not purely historical and may be accompanied by words such

5、 as“anticipates,”“may,”“forecasts,”“expects,”“intends,”“plans,”“potentially,”“believes,”“seeks,”“estimates,”and other words and terms of similar meaning.Such statements include,without limitation,the information provided regarding and expectations for future financial and operating performance,the s

6、ection captioned“Reiterate full year 2025 financial guidance,”expectations for financial performance in 2025,and statements regarding(i)expectations,development plans and timelines for Vertexs products and pipeline programs,including beliefs regarding the status of product launches,achievement of ke